Navigation Links


GenScript at Biology News

GenScript at Biology Products

Mouse Anti-Nop1p / Fibrillarin Monoclonal Antibody, Unconjugated, Clone A00104.01 from GenScript Corporation

Description:Mouse Anti Nop1p/Fibrillarin (monoclonal) Nop1p/Fibrillarin was originally identified as a nucleolar protein of bakers yeast, Saccharomyces cerevisiae (accession P15646). The Nop1p protein is essential for yeast viability and is localized in the nucleoli. The human homologue of Nop1p is fibrillarin (accession P22087) a component of the nucleolar small nuclear ribonucleoprotein (snRNP) partic...
Company:GenScript Corporation

Thermostable dUTPase from GenScript Corporation

Description:Thermostable dUTPase The thermostable dUTPase(pyrococcus fruriosus) maximizes the efficiency of high-fidelity PCR (using proofreading DNA polymerases). It removes contaminating dUTP present in PCR reactions and dNTP solutions. The presence of dUTPase in a proofreading DNA polymerase reaction can prevent dUTP misincorporation by maintaining dUTP levels below their inhibitory concentrations...
Company:GenScript Corporation

GCpro Taq DNA Polymerase Complete System from GenScript Corporation

Description:GCpro Taq DNA Polymerase is a versatile and easy-to use enzyme, with powerful advantages for all PCR applications. GCpro Taq DNA Polymerase is prepared from a recombinant clone expressed in E. coli, containing the DNA polymerase I gene from Thermococcus litoralis. The enzyme includes a highly processive 5'-3' DNA polymerase activity. Its inherent 3'-5' proofreading activity results in a greatly i...
Company:GenScript Corporation

Coating Stabilizer from GenScript Corporation

Description:This coating stabilizer is designed for stabilizing the coating biomolecules such as antigens and antibodies for immunoassay development. It can stabilize the coating molecules during the coating and drying process and for long term storage. It can also works as a blocking agent to block the remaining binding sites after coating....
Company:GenScript Corporation

Lyophilization Stabilizer from GenScript Corporation

Description:The lyophilization stabilizer is designed to stabilize the biomolecules during lyophilization process and for long-term storage. There are neither animal proteins nor toxic ingredients. It is a convenient 10 times solution in PBS, pH 7.2, and is superior to other traditional lyophilizing additives such as BSA, sucrose or treharose....
Company:GenScript Corporation

More>>

GenScript at Biology Technology
GenScript at Medicine News
GenScript at Medicine Products
GenScript at Medicine Technology
Other TagsFragmentFragmentFragmentMicroscopicMicroscopicAptamerRetroviralRetroviralPlanktonVietnamCompoundCompoundCompoundCompoundGifts
(Date:9/5/2008)...TA, Sept. 5 /PRNewswire/ -- EthicAd, a nonprofit o...ough consumer education, announces,the launch of a...ic better,understand direct-to-consumer (DTC) adve... Smart About Prescription Drug Advertising," is,ho...esearch and was,developed by the FDA in partnershi...
(Date:9/5/2008)...ton, DCWomen with hormone-receptor positive, metas... to help keep their cancer at bay, but when the tu...tment with chemotherapy becomes the only option. B... Cancer Symposiummay change this approach. Early ...sitize" the tumor, allowing anti-hormonal drugs to...
(Date:9/4/2008)...ork, NY, September 5, 2008Private Medicare Advanta... more per enrollee in 2008 compared to what the sa...icare fee-for-service program, according to a new ...yment reductions to MA plans mandated by the Medic... 2008 (MIPPA) scheduled to take effect beginning ...
(Date:9/4/2008)... want stronger labeling about fungal infection ris...) -- Federal health authorities have asked the man...rugs to bolster safety warnings on the risk of dev...drugs, Humira, Cimzia, Enbrel and Remicade, belong... factor alpha blockers (TNF-alpha blockers), which...
Breaking Medicine News(10 mins):Health News:Prescription Drug Advertising Subject of New FDA Web Site for Consumers 2Health News:1 step back ... 2 steps forward 2Health News:Extra payments to Medicare Advantage plans to total $8.5 billion in 2008 2Health News:FDA Demands Tougher Warnings on Immunosuppressive Drugs 2Health News:FDA Demands Tougher Warnings on Immunosuppressive Drugs 3
(Date:9/4/2008)... development of powerful supercomputers capable of...mark a technological milestone capable of bringing...eering, and business worldwide. Researchers at the... and Atmospheric Science, collaborating with NCAR ...Center for Ocean-Land-Atmospheric Studies) and the...
(Date:9/4/2008)...OR, N.Y. (Sept. 4, 2008) A variety of organismsf...iological rhythms, where the timing and duration o...justed to allow them to adapt and survive, even un...nt years, significant advances have been made to u... how they translate into modifications in cellular...
(Date:9/4/2008)...available in German . , Cystic kidney disease, ...ases of the excretory organs are characterized by ...racteristic proteins in the renal cells. An intern...ntists from DKFZ and Heidelberg University Hospita...estigate these conditions. , The researchers in...
(Date:9/4/2008)... San Antonio Breast Cancer Symposium features the ...ational and clinical breast cancer research. This ...eutic approaches, as well as strides being made in...elp you take the best advantage of the symposium,s...ncourage you to visit www.sabcs.org to view the ...
Breaking Biology News(10 mins):Petascale climate modeling heats up at University of Miami 2Petascale climate modeling heats up at University of Miami 3Interdisciplinary volume on biological rhythms serves as both primer and in-depth resource 2Gaining a better understanding of kidney diseases 2Martek Announces Settlement of OmegaTech Milestone Litigation 1290 1Martek Announces Settlement of OmegaTech Milestone Litigation 1290 2Pioneer in Reproductive Medicine Opens The Countrys First Comprehensive Fertility Practice 1286 1Pioneer in Reproductive Medicine Opens The Countrys First Comprehensive Fertility Practice 1286 2XTENT to Present CUSTOM I and CUSTOM II Trial Data at TCT 2007 533 1XTENT to Present CUSTOM I and CUSTOM II Trial Data at TCT 2007 533 2XTENT to Present CUSTOM I and CUSTOM II Trial Data at TCT 2007 533 3New UIC center to study drug choices safety 3777 1New UIC center to study drug choices safety 3777 2
Other Contentsangiographyangiographyangiographyangiographyfluoresceinfluoresceinfluoresceinfluoresceinfolicfolicfolicfolatefolatefontanellesadditivesadditivesadditivesadditivesadditivesguideguideguideguideguideguideguideguideguidefracturesfracturesfracturesfractures